April 1, 2020

To,
The Manager Listing,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai – 400 023

To,
The Manager Listing,
National Stock Exchange of India Limited
Exchange Plaza, C–1, Block – G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Sub: **Intimation of Record Date and Effective Date for Scheme of Amalgamation by way of merger by absorption among GlaxoSmithKline Consumer Healthcare Limited and Hindustan Unilever Limited and their respective shareholders and creditors**

Dear Sir/ Ma’am

This is further to our letters dated February 26, 2020 and March 13, 2020 where we had informed the exchange that the scheme by way of merger by absorption amongst GlaxoSmithKline Consumer Healthcare Limited ("Transferor Company") and Hindustan Unilever Limited ("Transferee Company") and their respective shareholders and creditors ("Scheme") has received the sanction of the Hon'ble National Company Law Tribunal ("NCLT"), Chandigarh bench.

In this regard, we wish to inform you that in accordance with the terms of the Scheme, the meeting of Board of Directors of the Transferor Company ("Board") was duly convened on Wednesday, April 1, 2020 which started at 10:30 AM and concluded at 11:40 AM. The Board *inter alia* considered and took on record the sanction of the Scheme by Hon'ble NCLT Mumbai Bench and Chandigarh Bench. Wednesday, April 1, 2020, has been fixed as the Effective Date of the Scheme and on which date the certified copy of the Hon'ble NCLT, Chandigarh Bench’s order will be filed with the Registrar of Companies.

The Appointed Date of the Scheme is April 1, 2020 i.e., the Effective Date, as set out in the Scheme and approved by the Hon'ble NCLT, Mumbai Bench and Chandigarh Bench. All the assets and liabilities of Transferor Company shall become assets and liabilities of the Transferee Company with effect from the Appointed Date.

In accordance with the Scheme, the shareholders of the Transferor Company as on the Record Date will be issued and allotted 4.39 (four decimal three nine) equity shares of the Transferee Company having a face value INR 1 (Indian Rupee One) each, as fully paid-up, for every 1 (one) equity share of the Transferor Company having a face value INR 10 (Indian Rupees Ten) each, held by them. In this regard, the Board of the Transferor Company has approved and fixed the Record Date as April 17, 2020.

We request you to kindly consider this as Notice under Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

CIN: L24231PB1968PLC002257
Registered Office
Patiala Road
Nabha (Punjab), India 147201
The equity shares to be issued and allotted by the Transferee Company in accordance with the Scheme will be listed and admitted for trading and on the relevant stock exchanges on which the existing equity shares of the Transferee Company are listed and shall rank pari passu in all respects with the existing equity shares of the Transferee Company. Please note that the shares issued by the Transferee Company shall remain frozen in the depository system till the time trading permission is obtained from the relevant stock exchanges.

Please take the same on record.

Thanking You,

For GlaxoSmithKline Consumer Healthcare Limited

Shanu Saksena

Company Secretary